Welcome to our dedicated page for FLUIDIGM (DELAWARE) news (Ticker: fldm), a resource for investors and traders seeking the latest updates and insights on FLUIDIGM (DELAWARE) stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FLUIDIGM (DELAWARE)'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FLUIDIGM (DELAWARE)'s position in the market.
Fluidigm Corporation reported a decrease in first quarter revenue of 8 percent, totaling $27.6 million, down from $30.1 million. The company experienced a GAAP net loss of $16 million, an improvement from a loss of $25.5 million a year prior. Key growth opportunities arose in the context of COVID-19, with customers seeking FDA Emergency Use Authorization for ultrahigh-throughput tests. Fluidigm is adapting to market changes by repositioning its products and managing operating expenses amid the pandemic.
Fluidigm Corporation (Nasdaq: FLDM) has launched its new Therapeutic Insights Services, providing mass cytometry and Imaging Mass Cytometry (IMC) services to researchers. This initiative aims to facilitate research by offering consultation, custom antibody sourcing, and data analysis tools. The services are particularly beneficial for customers affected by COVID-19 laboratory closures. In collaboration with Visikol, Fluidigm enhances access to IMC technology, allowing for rich data acquisition and analysis. The launch responds to the urgent need for advanced imaging tools in studying disease progression and therapeutic responses.